National HealthCare Corporation Common Stock (NHC)

FairStock Score: 58/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At the close on 2026-10-13, National HealthCare traded at $231.39, or 25.97 times earnings and 3.23 times book, both FairStock calculations. That is not a Graham bargain. The Graham Number of $119.86 leaves a margin of safety of -93.05%, so the market is paying a large premium for the company's asset and earnings history. The business itself is steady: in fiscal FY2025, filed figures show revenue of $1.5B, net income of $120.0M, and diluted EPS of $7.67, up from FY2024 revenue of $1.3B, net income of $101.9M, and EPS of $6.53. In fiscal Q2 2026, revenue was $378.4M, net income $40.3M, and EPS $2.54, versus $363.3M, $23.7M, and $1.52 in fiscal Q2 2025. That profit growth is real. Financial health is a strength: D/E is 0.03, Piotroski F-Score is 8/9, Altman Z-Score is 6.66, and trailing FCF is $146.5M, a 4.0% FCF yield. But ROCE is only 5.84%, revenue growth is 2.17%, and the PEG ratio is 2.29, so the price already assumes a lot. The Lynch category is STALWART, with 23.4% five-year profit growth and 9.5% revenue growth, according to FairStock. The moat is not obvious; skilled nursing and hospice are needed services, but reimbursement and regulation keep pricing power constrained. This is a decent, conservatively financed operator in an aging-demand industry, but the valuation is full. I would want a wider discount before getting excited.

In plain English: National HealthCare runs nursing homes, assisted living, and home health and hospice services. The company makes rising profits, has little debt, and generates steady cash, but the stock looks expensive compared with its earnings and book value. It is a solid business, though the price already reflects a lot of good news.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer